{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:18:14Z","timestamp":1774379894147,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.vaccine.2007.05.054","type":"journal-article","created":{"date-parts":[[2007,7,14]],"date-time":"2007-07-14T12:40:02Z","timestamp":1184416802000},"page":"6271-6276","source":"Crossref","is-referenced-by-count":23,"title":["Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus"],"prefix":"10.1016","volume":"25","author":[{"given":"Nicole D.","family":"Barab\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les P.","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh Q.H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.05.054_bib1","series-title":"Fields virology","first-page":"2265","article-title":"Alphaviruses","author":"Griffin","year":"2001"},{"key":"10.1016\/j.vaccine.2007.05.054_bib2","first-page":"89","article-title":"Western equine encephalomyelitis","volume":"vol. V","author":"Reisen","year":"1989"},{"key":"10.1016\/j.vaccine.2007.05.054_bib3","series-title":"Clinical virology","first-page":"1177","article-title":"Alphaviruses","author":"Tsai","year":"2002"},{"issue":"1","key":"10.1016\/j.vaccine.2007.05.054_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/CMR.7.1.89","article-title":"Medically important arboviruses of the United States and Canada","volume":"7","author":"Calisher","year":"1994","journal-title":"Clin Microbiol Rev"},{"issue":"806","key":"10.1016\/j.vaccine.2007.05.054_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/science.158.3806.1283","article-title":"Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards","volume":"158","author":"Hanson","year":"1967","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2007.05.054_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/444397","article-title":"Aerosol exposure to western equine encephalitis virus causes fever and encephalitis in cynomolgus macaques","volume":"192","author":"Reed","year":"2005","journal-title":"J Infect Dis"},{"issue":"1\/2","key":"10.1016\/j.vaccine.2007.05.054_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":"Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.vaccine.2007.05.054_bib8","first-page":"621","article-title":"Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses","volume":"39","author":"Barber","year":"1978","journal-title":"Am J Vet Res"},{"issue":"1","key":"10.1016\/j.vaccine.2007.05.054_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4269\/ajtmh.1971.20.146","article-title":"Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man","volume":"20","author":"Bartelloni","year":"1971","journal-title":"Am J Trop Med Hyg"},{"issue":"17\/18","key":"10.1016\/j.vaccine.2007.05.054_bib10","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.vaccine.2005.01.032","article-title":"Efficacy of DNA vaccination against western equine encephalitis virus infection","volume":"23","author":"Nagata","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4269\/ajtmh.2003.68.218","article-title":"Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates","volume":"68","author":"Turell","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/viro.2002.1677","article-title":"Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates","volume":"302","author":"Schoepp","year":"2002","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2007.05.054_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2007.05.054_bib14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2007.05.054_bib15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/mt.sj.6300120","article-title":"Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib16","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1371\/journal.ppat.0030025","article-title":"Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells","volume":"3","author":"Cheng","year":"2007","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2007.05.054_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.mt.6300130","article-title":"On the role of CD4(+) T Cells in the CD8(+) T-cell response elicited by recombinant adenovirus vaccines","volume":"15","author":"Yang","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2007.05.054_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","article-title":"Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response","volume":"76","author":"Molinier-Frenkel","year":"2002","journal-title":"J Virol"},{"issue":"5779","key":"10.1016\/j.vaccine.2007.05.054_bib19","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1126\/science.1124226","article-title":"Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys","volume":"312","author":"Letvin","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/hum.2005.16.157","article-title":"Adenovirus-based genetic vaccines for biodefense","volume":"16","author":"Boyer","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2007.05.054_bib21","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/507644","article-title":"Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen","volume":"194","author":"Chiuchiolo","year":"2006","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2007.05.054_bib22","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2005.04.014","article-title":"Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine","volume":"337","author":"Pacheco","year":"2005","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2007.05.054_bib24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/JVI.80.4.1959-1964.2006","article-title":"Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization","volume":"80","author":"Gao","year":"2006","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2007.05.054_bib25","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.vaccine.2006.09.047","article-title":"Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector","volume":"25","author":"Toro","year":"2007","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2007.05.054_bib26","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.vaccine.2004.06.056","article-title":"Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus","volume":"23","author":"Phillpotts","year":"2005","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2007.05.054_bib27","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/j.vaccine.2006.02.020","article-title":"Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination","volume":"24","author":"Perkins","year":"2006","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2007.05.054_bib28","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1016\/j.vaccine.2007.03.042","article-title":"Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine","volume":"25","author":"Wu","year":"2007","journal-title":"Vaccine"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2007.05.054_bib29","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1099\/vir.0.81815-0","article-title":"Infectivity variation and genetic diversity among strains of Western equine encephalitis virus","volume":"87","author":"Nagata","year":"2006","journal-title":"J Gen Virol"},{"issue":"5861","key":"10.1016\/j.vaccine.2007.05.054_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/297070a0","article-title":"Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis","volume":"297","author":"Schmaljohn","year":"1982","journal-title":"Nature"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2007.05.054_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1099\/vir.0.82685-0","article-title":"Adenovirus vector delivery stimulates natural killer cell recognition","volume":"88","author":"Tomasec","year":"2007","journal-title":"J Gen Virol"},{"issue":"5528","key":"10.1016\/j.vaccine.2007.05.054_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.1059742","article-title":"Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons","volume":"293","author":"Binder","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2007.05.054_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymthe.2006.02.015","article-title":"Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication","volume":"14","author":"Huarte","year":"2006","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2007.05.054_bib34","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.4049\/jimmunol.178.6.3505","article-title":"Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus","volume":"178","author":"Zhu","year":"2007","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2007.05.054_bib35","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1128\/JVI.01152-06","article-title":"Synergistic roles of antibody and interferon in noncytolytic clearance of sindbis virus from different regions of the central nervous system","volume":"81","author":"Burdeinick-Kerr","year":"2007","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2007.05.054_bib36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"Aids"},{"issue":"15","key":"10.1016\/j.vaccine.2007.05.054_bib37","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2007.05.054_bib38","doi-asserted-by":"crossref","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.05.054_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","article-title":"Chimpanzee adenovirus vaccine protects against Zaire Ebola virus","volume":"346","author":"Kobinger","year":"2006","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2007.05.054_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1998.9351","article-title":"Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD","volume":"250","author":"Zakhartchouk","year":"1998","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2007.05.054_bib41","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol"},{"issue":"7090","key":"10.1016\/j.vaccine.2007.05.054_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.vaccine.2007.05.054_bib43","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.gt.3302792","article-title":"Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors","volume":"13","author":"Mane","year":"2006","journal-title":"Gene Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07006342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07006342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T01:39:24Z","timestamp":1556674764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07006342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":43,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0264410X07006342"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.05.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}